These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
751 related articles for article (PubMed ID: 29596039)
1. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk. Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039 [TBL] [Abstract][Full Text] [Related]
2. Thyroid cytology-nuclear versus architectural atypia within the "Atypia of undetermined significance/follicular lesion of undetermined significance" Bethesda category have significantly different rates of malignancy. Gan TR; Nga ME; Lum JH; Wong WM; Tan WB; Parameswaran R; Ngiam KY Cancer Cytopathol; 2017 Apr; 125(4):245-256. PubMed ID: 28192631 [TBL] [Abstract][Full Text] [Related]
3. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results. Hyeon J; Ahn S; Shin JH; Oh YL Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408 [TBL] [Abstract][Full Text] [Related]
4. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology. Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883 [TBL] [Abstract][Full Text] [Related]
5. Follicular lesion of undetermined significance in thyroid FNA revisited. Walts AE; Mirocha J; Bose S Diagn Cytopathol; 2014 Jan; 42(1):18-22. PubMed ID: 23894017 [TBL] [Abstract][Full Text] [Related]
6. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma. Evranos B; Polat SB; Baser H; Ozdemir D; Kilicarslan A; Yalcin A; Ersoy R; Cakir B Cytopathology; 2017 Aug; 28(4):259-267. PubMed ID: 27666595 [TBL] [Abstract][Full Text] [Related]
7. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System. Sullivan PS; Hirschowitz SL; Fung PC; Apple SK Cancer Cytopathol; 2014 Dec; 122(12):866-72. PubMed ID: 25078420 [TBL] [Abstract][Full Text] [Related]
8. The Bethesda system for reporting thyroid cytopathology: an institutional experience of the outcome of indeterminate categories. Onder S; Firat P; Ates D Cytopathology; 2014 Jun; 25(3):177-84. PubMed ID: 23998291 [TBL] [Abstract][Full Text] [Related]
9. Impact of the Reclassification of "Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma" to "Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features" on the Bethesda System for Reporting Thyroid Cytopathology: A Large Academic Institution's Experience. Lau RP; Paulsen JD; Brandler TC; Liu CZ; Simsir A; Zhou F Am J Clin Pathol; 2017 Dec; 149(1):50-54. PubMed ID: 29272354 [TBL] [Abstract][Full Text] [Related]
10. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists. Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980 [TBL] [Abstract][Full Text] [Related]
11. Importance of cytological subclassification of thyroid nodules with Bethesda category III cytology (AUS/FLUS) into architectural atypia only and nuclear atypia: A prospective study. Rosario PW; Calsolari MR Diagn Cytopathol; 2017 Jul; 45(7):604-607. PubMed ID: 28425211 [TBL] [Abstract][Full Text] [Related]
12. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Faquin WC; Wong LQ; Afrogheh AH; Ali SZ; Bishop JA; Bongiovanni M; Pusztaszeri MP; VandenBussche CJ; Gourmaud J; Vaickus LJ; Baloch ZW Cancer Cytopathol; 2016 Mar; 124(3):181-7. PubMed ID: 26457584 [TBL] [Abstract][Full Text] [Related]
13. Implementing noninvasive follicular thyroid neoplasm with papillary-like nuclear features may potentially impact the risk of malignancy for thyroid nodules categorized as AUS/FLUS and FN/SFN. Li W; Sciallis A; Lew M; Pang J; Jing X Diagn Cytopathol; 2018 Feb; 46(2):148-153. PubMed ID: 29193839 [TBL] [Abstract][Full Text] [Related]
14. Reclassification of cytologically atypical thyroid nodules based on radiologic features in pediatric patients. Arva NC; Deitch SG J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):753-60. PubMed ID: 25879311 [TBL] [Abstract][Full Text] [Related]
15. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations. Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940 [TBL] [Abstract][Full Text] [Related]
16. An institutional experience: A retrospective analysis of the effect of transitioning from follicular lesion of undetermined significance to atypia of undetermined significance with subclassified atypia on interobserver concordance, rates of neoplasia, and rates of malignancy. Kroll-Wheeler L; Cantley R; Pang JC; Soles BS; Smola B; Jing X; Lew M Diagn Cytopathol; 2021 Jan; 49(1):31-38. PubMed ID: 32936526 [TBL] [Abstract][Full Text] [Related]
17. Impact of the modification of the diagnostic criteria in the 2017 Bethesda System for Reporting Thyroid Cytopathology: a report of a single institution in Japan. Higuchi M; Hirokawa M; Kanematsu R; Tanaka A; Suzuki A; Yamao N; Hayashi T; Kuma S; Miyauchi A Endocr J; 2018 Dec; 65(12):1193-1198. PubMed ID: 30282887 [TBL] [Abstract][Full Text] [Related]
18. ThyroSeq v3 for Bethesda III and IV: An institutional experience. Desai D; Lepe M; Baloch ZW; Mandel SJ Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808 [TBL] [Abstract][Full Text] [Related]
19. Thyroid cytology in Pakistan: An institutional audit of the atypia of undetermined significance/follicular lesion of undetermined significance category. Fatima S; Qureshi R; Imran S; Idrees R; Ahmad Z; Kayani N; Ahmed A Cytopathology; 2021 Mar; 32(2):205-210. PubMed ID: 33098589 [TBL] [Abstract][Full Text] [Related]
20. Impact of Reclassification on Thyroid Nodules with Architectural Atypia: From Non-Invasive Encapsulated Follicular Variant Papillary Thyroid Carcinomas to Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Jeon MJ; Song DE; Jung CK; Kim WG; Kwon H; Lee YM; Sung TY; Yoon JH; Chung KW; Hong SJ; Baek JH; Lee JH; Kim TY; Shong YK; Kim WB PLoS One; 2016; 11(12):e0167756. PubMed ID: 27936121 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]